Development of physiologically based toxicokinetic models for improving the human indoor exposure assessment to water contaminants: trichloroethylene and trihalomethanes

Approaches for evaluating the relevance of multiroute exposures in establishing guideline values for drinking water contaminants

In establishing the guideline values for chemical contaminants in drinking water, the contribution of inhalation and dermal routes associated with showering/bathing needs to be evaluated. The present article reviews the current approaches available for evaluating the importance of inhalation and dermal routes of exposure to drinking water contaminants (DWCs) and integrates them within a 2-tier approach. Accordingly, tier 1 would evaluate whether the dermal or inhalation route is likely to contribute to at least 10% of the dose received from ingestion of drinking water (i.e., 0.15 L-equivalent per day based on the daily water intake rate of 1.5 L/day typically used in Health Canada assessments). Based on the route-specific exposure parameters (i.e., area of skin exposed, effective skin permeability coefficient [K(p)], and air to water concentration ratio during use conditions [F(air-water)], breathing rate, duration of contact, and fraction absorbed), it was determined that for DWCs with K(p) less than 0.024 cm/hr and F(air - water) less than 0.0063, the dermal and inhalation routes during showering or bathing are unlikely to contribute significantly to the total dose. For DWCs with K(p) value equal to or greater than 0.025 cm/hr, dermal notation is implied, and as such, tier 2 calculation of L-equivalent associated with dermal exposure needs to be performed. Similarly, for DWCs with F(air-water) greater than 0.00063, inhalation notation is implied, and detailed evaluation of the L-equivalent associated with inhalation exposure (i.e., tier 2) is suggested. In general, data from human volunteer studies, observational measurements, and targeted modeling studies are useful for deriving L-equivalents, reflective of the magnitude of dose received via dermal and inhalation routes relative to the oral route. However, in resource-limited situations, these approaches can be integrated within a 2-tier approach for prioritizing and providing quantitative evaluations of the relevance of dermal and inhalation routes for developing exposure guidelines for DWCs.

Physiologically based pharmacokinetic modeling of persistent organic pollutants for lifetime exposure assessment: a new tool in breast cancer epidemiologic studies

BACKGROUND

Despite experimental evidence, most epidemiologic studies to date have not supported an association between exposure to persistent organic pollutants (POP) and breast cancer incidence in humans. This may be attributable to difficulties in estimating blood/tissue POP concentration at critical time periods of carcinogenesis.

OBJECTIVES

In this work we aimed to develop a tool to estimate lifetime POP blood/tissue exposure and levels during any hypothesized time window of susceptibility in breast cancer development.

METHODS

We developed a physiologically based pharmacokinetic (PBPK) model that can account for any given physiologic lifetime history. Using data on pregnancies, height, weight, and age, the model estimates the values of physiologic parameters (e.g., organ volume, composition, and blood flow) throughout a woman's entire life. We assessed the lifetime toxicokinetic profile (LTP) for various exposure scenarios and physiologic factors (i.e., breast-feeding, growth, pregnancy, lactation, and weight changes).

RESULTS

Simulations for three POPs [hexachlorobenzene, polychlorinated biphenyl (PCB)-153, PCB-180] using different lifetime physiologic profiles showed that the same blood concentration at 55 years of age can be reached despite totally different LTP. Aside from exposure levels, lactation periods and weight profile history were shown to be the factors that had the greatest impact on the LTP.

CONCLUSIONS

This new lifetime PBPK model, which showed the limitations of using a single sample value obtained around the time of diagnosis for lifetime exposure assessment, will enable researchers conducting environmental epidemiology studies to reduce uncertainty linked to past POP exposure estimation and to consider exposure during time windows that are hypothesized to be mechanistically critical in carcinogenesis.

The healthy men study: an evaluation of exposure to disinfection by-products in tap water and sperm quality

BACKGROUND

Chlorination of drinking water generates disinfection by-products (DBPs), which have been shown to disrupt spermatogenesis in rodents at high doses, suggesting that DBPs could pose a reproductive risk to men. In this study we assessed DBP exposure and testicular toxicity, as evidenced by altered semen quality.

METHODS

We conducted a cohort study to evaluate semen quality in men with well-characterized exposures to DBPs. Participants were 228 presumed fertile men with different DBP profiles. They completed a telephone interview about demographics, health history, water consumption, and other exposures and provided a semen sample. Semen outcomes included sperm concentration and morphology, as well as DNA integrity and chromatin maturity. Exposures to DBPs were evaluated by incorporating data on water consumption and bathing and showering with concentrations measured in tap water. We used multivariable linear regression to assess the relationship between exposure to DBPs and adverse sperm outcomes.

RESULTS

The mean (median) sperm concentration and sperm count were 114.2 (90.5) million/mL and 362 (265) million, respectively. The mean (median) of the four trihalomethane species (THM4) exposure was 45.7 (65.3) microg/L, and the mean (median) of the nine haloacetic acid species (HAA9) exposure was 30.7 (44.2) microg/L. These sperm parameters were not associated with exposure to these classes of DBPs. For other sperm outcomes, we found no consistent pattern of increased abnormal semen quality with elevated exposure to trihalomethanes (THMs) or haloacetic acids (HAAs). The use of alternate methods for assessing exposure to DBPs and site-specific analyses did not change these results.

CONCLUSIONS

The results of this study do not support an association between exposure to levels of DBPs near or below regulatory limits and adverse sperm outcomes in humans.

Disposition of Bromodichloromethane in Humans Following Oral and Dermal Exposure

Exposure to bromodichloromethane (BDCM), one of the most prevalent disinfection byproducts in drinking water, can occur via ingestion of water and by dermal absorption and inhalation during activities such as bathing and showering. The objectives of this research were to assess BDCM pharmacokinetics in human volunteers exposed percutaneously and orally to (13)C-BDCM and to evaluate factors that could affect disposition of BDCM. Among study subjects, CYP2E1 activity varied fourfold; 20% had the glutathione S-transferase theta 1-1 homozygous null genotype; and body fat ranged from 7 to 22%. Subjects were exposed to (13)C-BDCM in water (target concentration of 36 mug/l) via ingestion and by forearm submersion. Blood was collected for up to 24 h and analyzed for (13)C-BDCM by solid-phase microextraction and high-resolution GC-MS. Urine was collected before and after exposure for mutagenicity determinations in Salmonella. After ingestion (mean dose = 146 ng/kg), blood (13)C-BDCM concentrations peaked and declined rapidly, returning to levels near or below the limit of detection (LOD) within 4 h. The T(max) for the oral exposure ranged from 5 to 30 min, and the C(max) ranged from 0.4 to 4.1 ng/l. After the 1 h dermal exposure (estimated mean dose = 155 ng/kg), blood concentrations of (13)C-BDCM ranged from 39 to 170 ng/l and decreased to levels near or below the LOD by 24 h. Peak postdose urine mutagenicity levels that were at least twice that of the predose mean level occurred in 6 of 10 percutaneously exposed subjects and 3 of 8 orally exposed subjects. These results demonstrate a highly significant contribution of dermal absorption to circulating levels of BDCM and confirm the much lower oral contribution, indicating that water uses involving dermal contact can lead to much greater systemic BDCM doses than water ingestion. These data will facilitate development and validation of physiologically based pharmacokinetic models for BDCM in humans.